Novo Nordisk Challenges Pfizer's $4.9B Deal for Obesity Startup Metsera

Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.